Progressive multifocal leukoencephalopathy with natalizumab extended or standard interval dosing in the United States and the rest of the world

CONCLUSIONS: This analysis provides insights on PML in patients receiving natalizumab that extend current knowledge, particularly regarding PML in patients receiving natalizumab EID, which can be built upon in the future.PMID:37272350 | DOI:10.1080/14740338.2023.2221027

Source: Expert Opinion on Drug Safety - June 5, 2023 Category: Drugs & Pharmacology Authors: Liesel Dsilva Kerry McCarthy Jennifer Lyons Bernadette Cabigas Nolan Campbell George Kong Bryan Adams Robert Kuhelj Priya Singhal Karen Smirnakis Source Type: research